Tokyo, March 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060958) titled 'Role of dysregulated cholesterol metabolism in the pathogenesis of metabolic dysfunction-associated fatty liver disease' on March 17.
Study Type:
Observational
Primary Sponsor:
Institute - Tokyo Medical University
Condition:
Condition - Metabolic dysfunction-associated steatotic liver disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to clarify the significance of impaired cholesterol metabolism in the pathogenesis of MASLD by comparing the frequency of cholesterol crystallization in the liver with pathological findings related to fibrosis, inflammation, and steatosis. It also aims to identify circulating biomarkers that reflect cholesterol crystallization and to develop a diagnostic method for metabolic dysfunction-associated steatohepatitis (MASH) based on disordered cholesterol metabolism.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with suspected MASLD who are scheduled for liver biopsy
Key exclusion criteria - Presence of other liver diseases, including alcohol-related liver disease, drug-induced liver injury, viral hepatitis, autoimmune liver disease, and metabolic liver diseases
Patients considered unsuitable for this study by the principal investigator or sub-investigator
Patients who do not provide consent to participate in this study
Target Size - 50
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 12 Month 10 Day
Date of IRB - 2026 Year 02 Month 05 Day
Anticipated trial start date - 2026 Year 03 Month 17 Day
Last follow-up date - 2029 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069755
Disclaimer: Curated by HT Syndication.
